We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,388

Appeal relating to double patenting and sufficiency of tadalafil patent dismissed
  • Borden Ladner Gervais LLP
  • Canada
  • November 9 2016

The Federal Court of Appeal considered an appeal from Apotex relating to double patenting and insufficiency of a patent claiming the use of tadalafil


Supreme Court of Canada Reserves Decision on Utility of AstraZeneca's NEXIUM Patent
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • November 8 2016

The Supreme Court of Canada today heard oral arguments in AstraZeneca v Apotex and reserved its decision. In a case that raises the propriety of the


Supreme Court of Canada hears important appeal regarding the “promise doctrine"
  • Marks & Clerk
  • Canada
  • November 9 2016

The Supreme Court of Canada heard oral arguments on November 8, 2016 in an important appeal challenging the "promise of the patent" utility doctrine


Pharmaceutical patent rights get a boost in Canada under CETA-driven legislation
  • Marks & Clerk
  • Canada
  • November 14 2016

After years of negotiations, the Comprehensive Economic and Trade Agreement (CETA) between Canada and Europe was finally approved by all 28 European


Methods of medical treatment and dosage claims
  • Gowling WLG
  • Canada
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada


CETA Implementation in Canada - Implications of Bill C-30 on the Pharmaceutical Industry
  • DLA Piper LLP
  • Canada
  • November 3 2016

Bill C-30 presents significant changes to Canada’s pharmaceutical landscape by introducing supplementary protection for pharmaceutical products and


We Promise that it is Still Worthwhile to File Pharma Patents in Canada
  • Bereskin & Parr LLP
  • Canada
  • November 10 2016

The “promise doctrine” is getting a lot of press in the pharma industry. We know that some big pharma companies are ticked off, for example, from Eli


Fresenius’ notice of allegation of non-infringement for moxifloxacin hydrochloride found defective
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 31 2016

On July 5, 2016, the Federal Court granted an order prohibiting the Minister of Health from issuing a notice of compliance (NOC) to Fresenius for its


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Markush claims can pose a risk of patent invalidity
  • Gowling WLG
  • Canada
  • June 28 2011

As patent law in Canada continues to evolve in significant ways, it is important to remind ourselves of cases from the past few years that continue to impact patent drafting today and to influence the validity of patents, especially pharmaceutical patents in Canada